Abstract：【Objective】To investigate the effect of compound Kushen injection combined with Docetaxel on serum tumor markers in patients with non-small cell lung cancer (NSCLC) after the failure of first-line chemotherapy treatment.【Methods】A total of 80 patients with NSCLC after the failure of first-line chemotherapy treatment were randomly divided into observation group (treated with compound Kushen injection combined with docetaxel) and control group (treated with docetaxel). The short-term efficacy, adverse reactions, serum tumor markers levels before and after treatment and changes of cellular immune function were compared between the two groups, OS and PFS of the two groups were statistically analyzed.【Results】The short-term effective rate and disease control rate of the observation group were 25% (10/25) and 62.50% (25/40), respectively, which were significantly higher than 10% (4/40) and 37.50% (15, 40) of the control group, and the difference was significant (P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05);Compared with before treatment, the levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen -125 (CA-125) and cytokeratin 19 fragment (CYFRA21 - 1) were significantly decreased in the two groups after treatment (P<0.05), and the above indexes in the observation group were significantly lower than those in the control group (P<0.05);The median OS and PFS in the observation group were 13.50 months and 9 months respectively, which were significantly longer than those in the control group at 10.20 months and 7.40 months, and the difference was significant (P<0.05).【Conclusion】Compound Kushen injection combined with docetaxel can significantly reduce the serum tumor markers in patients with NSCLC, improve the cellular immune function, prolong OS, PFS, and do not increase toxicity
白晶. 复方苦参注射液联合多西他赛治疗一线化疗失败非小细胞肺癌患者的疗效[J]. 医学临床研究, 2017, 34(10): 1927-1929.
BAI Jing. Effect of Compound Kushen Injection Combined with Docetaxel on NSCLC Patient after the Failure of First-line Chemotherapy Treatment. JOURNAL OF CLINICAL RESEARCH, 2017, 34(10): 1927-1929.
2017, Vol. 34 
